SAN FRANCISCO, Oct. 2 /PRNewswire-FirstCall/ -- Epiphany Biosciences, Inc. announced today that Dr. Charles Sanders has accepted the position of Lead Director. Dr. Sanders is a highly experienced biotechnology and pharmaceutical executive, currently serving as Lead Director of Genentech. He has also served as chief executive officer of Glaxo Inc., from 1989-1994 and chairman of the board from 1992-1995. In addition, Dr. Sanders is also a member of the Boards of Directors of Vertex Pharmaceuticals, Cephalon, Inc., and Icagen, Inc.
"The Epiphany strategy of addressing long-term disease as sequelae of chronic viral infection offers a unique perspective in addressing unmet medical needs in a variety of patients. Dr. Volinsky has assembled an outstanding team and I am happy to work with them to reach their goals," reported Dr. Sanders.
"We are elated to have Dr. Sanders as our Lead Director. His extensive experience in the biotechnology industry has already helped propel Epiphany forward and we look forward to his continued input and counsel," stated Fred Volinsky, MD, the Chief Executive Officer of Epiphany Biosciences.
"Next year will be a critically important time for the company as we plan to collect data from up to four Phase 2 studies as well as continue further development of our HCV pipeline," commented Brian Murphy, MD, Chief Medical Officer of Epiphany. "Dr. Sanders' guidance will be very valuable at this pivotal time."
About Epiphany Biosciences:
Epiphany Biosciences is a privately-held company developing therapeutic products and diagnostic technologies that treat or help prevent the spread of pathogenic viruses, including varicella virus (VZV), Epstein-Barr Virus (EBV) and hepatitis C virus (HCV).
CONTACT: Fred Volinsky, CEO of Epiphany Biosciences, Inc., +1-415-765-7193
Web site: http://www.epiphanybio.com/
